Wednesday, March 31, 2010

Multiple Sclerosis: Could This Be The Cure?

Multiple Sclerosis: Could This Be The Cure?
Multiple sclerosis (MS) is a chronic disease characterized by pain and disability. The most common symptoms of MS are vision problems, muscle weakness, numbness and loss of balance and coordination. In extreme cases, hearing loss, speech impediment, paralysis and cognitive impairment may also manifest. 

Bookmark and Share

Tuesday, March 30, 2010

MS Society of Canada

We've put a team together (Team MacDonald) and we're walking for MS. If you can help...please, pledge me. We need to  endMS. Thank You so much.
MS Society of Canada

Bookmark and Share

Monday, March 29, 2010

One Step Closer To Personalized Medicine: Researchers Find First Bio-Marker For MS

Researchers at the University of Alabama at Birmingham (UAB) have found the first bio-marker for multiple sclerosis (MS) that might predict which patients will respond to a standard therapy and which will not.
Click here to read more One Step Closer To Personalized Medicine: Researchers Find First Bio-Marker For MS

Bookmark and Share

New treatment for MS

Almost six months later, and 80 years since the theory of chronic cerebral spinal venous insufficiency (CCSVI) was first proposed, Canadians are spending as much as $20,000 to be treated in other countries like the U.S., India and Poland. Why?
click here to read more

Bookmark and Share
Federal health officials warned doctors Friday that the risk of a deadly brain inflammation linked to the multiple sclerosis treatment Tysabri increases with use of the drug.

Bookmark and Share
Multiple Sclerosis informational site. Will link up to may other sites.
Try it... see what you think...

Bookmark and Share

Thursday, March 25, 2010

March 24, 2010
Statscan finds widespread vitamin D deficiency in Canadians
By Martin Mittelstaedt
From Wednesday's Globe and Mail
Survey says 2 out of 3 Canadians have less of the nutrient than the latest research suggests is
Bookmark and Share

Banking on the future: Your newborn's umbilical cord blood could save a life

Banking on the future: Your newborn's umbilical cord blood could save a life
It's believed they could be used to repair damage after a stroke, a heart attack or spinal cord injury, or play a role in treating diabetes, Parkinson's and multiple sclerosis.

Bookmark and Share

reBlog from The Wheelchair Kamikaze: Wheelchair Kamikaze

Although I'm not a hero, I do live with one. My wife Karen displays, each and every day, the quiet bravery and steadfastness that truly define the word. I was diagnosed just one year after we were married, and in the seven years since, Karen has quite literally been by my side through innumerable treatment sessions and doctors conferences, and suffered with me the long series of raised hopes and shattering disappointments that have defined the course of my disease. Without her, I very well may have checked out a long time ago. I'm stuck with myself and my situation, forced to experience the slow withering away of the "me" I once knew. Karen is here by choice; neither I nor any of my friends or family would have blamed her one bit if at any time along the way she had simply opted out. "In sickness and in health" sounds great in concept, but in practice it's one hell of a promise to keep.The Wheelchair Kamikaze, Wheelchair Kamikaze, Mar 2010
You should read the whole article.

MS Program Halted Amid Controversy

After Patients Push for Experimental Treatment, Doctors Conclude It's Too Risky

Stanford University vascular specialist Michael D. Dake has done pioneering work at the hospital's cardiac-catheterization labs, like fixing certain aortic aneurysms once thought untreatable.
[MS] Stanford Office of Communication & Public Affairs
Michael Dake is at the center of an uproar over a novel MS treatment.
But Dr. Dake's experimenting touched off a furor at the university recently when—based on preliminary research by an Italian surgeon—he inserted metal stents into the internal jugular veins of multiple sclerosis patients. Doctors are generally allowed to adapt for new uses devices, like stents, that have received Food and Drug Administration approval.
In December, Dr. Dake's 40-patient MS stenting program was shut down, according to Stanford officials. A number of patients treated by Dr. Dake had reported improvements in their symptoms following the procedure. However, one patient died of a brain hemorrhage on the way home from treatment and another had to undergo life-saving emergency surgery. Neurologists from Stanford and the University of California, San Francisco, had protested to Stanford medical school officials that the procedure was too untested to be used in people. It's not clear which factors contributed to the program's ending.
Philip A. Pizzo, the Stanford medical school dean, confirmed that after talking to the doctors involved in the matter, "it was decided there would not be further procedures." But he said the vascular theory for MS shows enough promise to be studied further. He says he has asked Stanford doctors, including Dr. Dake and some of his critics, to collaborate on research into whether MS patients have a significantly higher rate of obstructions in their jugular veins than do people without the disease.
The controversy at Stanford illustrates the pressure that groups of patients can bring to bear on medical researchers looking into promising, but untested, cures for major illnesses. Internet chat rooms for MS patients last year were filled with comments about recent research by vascular surgeon Paolo Zamboni of the University of Ferrara, Italy. Dr. Zamboni's findings—that blockages in the jugular veins were causing or worsening MS symptoms—have led to additional research at other universities in the U.S., as well as in Poland and Jordan. Hundreds of patients have signed up for imaging programs to measure jugular-vein blockages at various institutions, including State University of New York-Buffalo, Georgetown University and McMaster University in Canada.
Multiple sclerosis has confounded physicians since it was first described in 1868. In MS, the myelin sheath that insulates nerves disintegrates. It is generally thought of as an autoimmune disease, meaning a patient's body attacks its own cells. Symptoms vary widely but often involve progressive muscle weakness and pain that can flare up unpredictably.
Decades of research have resulted in drugs like beta-interferon and, more recently, Tysabri, which ward off relapses in thousands of patients. But beta-interferon carries flu-like side effects and Tysabri has led to fatal brain disease in rare instances.
Dr. Zamboni, whose wife has MS, studied 65 patients with the disease and found that more than half of them had jugular blockage. That compared with no such blockages in a group of 235 non-MS patients. (Other similar studies have found jugular blockages in roughly 20% of non-MS patients.)
In late 2008, Dr. Zamboni reported his findings in a European medical journal. He theorized that blockages were causing changes in the brain that were triggering MS symptoms. If the veins could be opened, he and doctors at other institutions have suggested in scientific papers that perhaps the symptoms would cease.
He began treating patients with balloon angioplasty to prop open veins. In an interview, Dr. Zamboni says some patients had a "practically complete recovery" while more severely ill ones had "simple improvement in their quality of life."
Joan Beal, a Los Angeles woman whose husband has MS, heard about Dr. Zamboni's findings on the Internet and began hunting for a U.S. doctor who could perform the procedure. Adopting the chat room name Cheerleader, Ms. Beal became just that for Dr. Zamboni's work. Her online postings helped fire up other patients to push for testing and treatment, patients say. Ms. Beal got in touch with a Stanford doctor and author, who referred her husband's case to Dr. Dake.
Dr. Dake says he initially thought the idea was "wacky." He says he changed his mind after reading more about Dr. Zamboni's theory and started seeing MS patients Ms. Beal referred to him. Starting last summer, he used balloon angioplasty and stents to open up veins.
The first to get a stent was Ms. Beal's husband, Jeff Beal, a composer for television and movies. After the procedure, Mr. Beal gave up his daily naps and was far more energetic and alert, his wife says. Some other patients tell similar stories. Randi Cohen says some of her MS symptoms, including fatigue, have significantly improved since Dr. Dake placed a stent in her jugular vein. "I never have to think about pacing myself" since having the stent installed, she says.
Some doctors say the procedure is highly experimental and the improvements reported by patients could simply be a placebo effect, since the course of the MS disease is so unpredictable. Stephen L. Hauser, chairman of neurology at UC, San Francisco, says it's "extremely unlikely" any vascular cause, such as vein blockage, could be the main culprit in MS.
Dr. Dake responds that critical neurologists "don't want to acknowledge that a vascular surgeon in Italy found something that's been right under their noses."
Complications in two cases undermined Dr. Dake's efforts. One patient, Holly Shean from Prescott, Ariz., died of a brain hemorrhage on a flight home after treatment by Dr. Dake in August. Ms. Shean was treated with the blood-thinner Coumadin, which carries a bleeding risk, and had a stent installed in one jugular vein, and later in the other, according to her sister, Trudy Roughgarden. She says Ms. Shean, who used a wheelchair, "felt a little improvement in her fatigue level," after treatment. There is no evidence that the stents contributed to the hemorrhage.
Later, a young scientist from Berkeley, Calif., who was a patient of Dr. Hauser's, read about Dr. Dake's work and had a stent put in, according to interviews with him, Dr. Hauser and Stanford doctors familiar with the case. The stent broke free, floated into the man's heart and had to be removed with emergency surgery, these people say.
Dr. Dake says he had just seen Ms. Shean for a "follow-up visit" before she died on the plane home. He says he can't discuss an individual patient's care, due to rules governing patient confidentiality.
Dr. Hauser complained about Dr. Dake's work to neurology colleagues at Stanford, who also grew concerned that the procedure was overly experimental and potentially dangerous, these doctors say. Stanford MS specialist Lawrence Steinman says Dr. Dake's work "needed more strenuous oversight."
Dr. Dake says he was performing clinical work that he believed would help MS patients. He says such work is necessary before scientists can initiate a research program that would require formal oversight.
After meeting with the Stanford medical dean and Stanford lawyers, Dr. Dake says he stopped stenting MS patients in December. Now, he says, "I'm sort of viewed as the crazy uncle locked up in the woodshed out back."
Write to Thomas M. Burton at
Bookmark and Share

Tuesday, March 23, 2010

WASHINGTON (AP) -- Under intense pressure from patients, some U.S. doctors are cautiously testing a provocative theory that abnormal blood drainage from the brain may play a role in multiple sclerosis -- and that a surgical vein fix might help.

Bookmark and Share

Friday, March 19, 2010

CCSVI Q&A with Dr. Simka & Dr. Godley. Held at False Creek Healthcare Centre. Concludes with Dr. Simka explaining the procedure: diagnostic tests, pathology and venography (Liberation).

Press coverage by MS Liberation Group

Filmed by Vidyn Media

The new video is here:
Bookmark and Share
CSVI Press Conference at False Creek Healthcare Centre

Bookmark and Share

Q :

What steps would be required before a treatment for CCSVI (Chronic Cerebrospinal Venous Insufficiency) would be declared safe and recommended?
How long does it typically take to become available in Canada?

A :
The theory that chronic cerebrospinal venous insufficiency may play a role in MS has generated a huge amount of interest after the media reported on the work of an Italian researcher, Dr. Zamboni. He reported that abnormalities in the major veins draining the brain and spinal cord (the internal jugular and azygos veins), were always narrowed in people with MS, and were never narrowed in people without MS, and that opening these areas of narrowing might result in benefit.

Other researchers are now working hard at trying to quickly replicate and determine the significance of his findings.

Firstly, researchers have been trying to confirm the existence of these proposed venous abnormalities and then to determine how these abnormalities might contribute to the MS disease process.

The group of researchers at the Buffalo Neuroimaging Analysis Center recently announced their results with the first 500 patients studied with the same technique employed by Dr. Zamboni (Combined Transcranial and Extracranial Venous Doppler Ultrasound). They have just announced the preliminary results and plan to present more detailed results at the American Academy of Neurology meeting in Toronto in mid April. They used Dr. Zamboni's technique to determine the presence of venous abnormalities in people with MS and age matched "controls" (people without MS). They used Dr. Zamboni's criteria for considering someone to have CCSVI. They reported that the abnormalities were present in 55% of people with MS and 26 % of the people without MS. Another 10 % of MS patients were "borderline". This is quite different than Dr. Zamboni's results of finding the abnormality in 100% of people with MS and 0% of controls. It raises the possibility that the venous abnormalities may be associated with, or a risk factor for MS, rather than a cause, although this hasn’t yet been determined with certainty. Thanks to an increase in funding generated by interest in the topic from people across North America, other groups across Canada and the U.S. also have studies planned or underway to investigate the presence of and significance of venous abnormalities in MS.

All of these results are eagerly anticipated to help us define exactly what the relationship is between these venous abnormalities and MS. There are many questions left to be answered including (as just a small sampling): are these areas of narrowing true constrictions or simply areas of variable collapsing and expansion normally seen in veins, how could these venous abnormalities contribute to MS, how can we explain the absence of venous abnormalities in a significant proportion of people with MS if it really contributes substantially to the disease, why do some people with these venous abnormalities not develop MS (a full 26% of the non-MS population in the Buffalo study), how come people with venous abnormalities after procedures like the insertion of a central line in the jugular vein not develop MS even though their internal jugular vein can become closed off, how could the four patterns of venous abnormalities described by Dr. Zamboni account for the tremendous variability in the disease, how do the venous abnormalities tie in with the known effect of vitamin D levels on the population risk of MS, how come immunomodulatory and immunosuppressive therapies work in MS if it is a blood flow problem, why do we see the immune abnormalities in the blood and spinal fluid of people with MS if it’s a vascular problem and many, many others.

Dr. Zamboni also reported on a small study of 65 people, 35 with relapsing-remitting MS and 30 with progressive forms of MS (20 with secondary progressive MS and 10 with primary progressive MS), in which he used a balloon catheter inserted into these veins, and by inflating the balloon, reversed the narrowing (venoplasty). He reported his results in a paper published in the December issue of the Journal of Vascular Surgery. The procedure was successful at keeping the azygous open in most cases, although a stent was used in one case to keep it open. In the internal jugular vein, the re-narrowing rate was 47 % over the subsequent months and required that the procedure be re-done. He could not use a stent in this vein as the currently available stents (designed for arteries not veins) were felt to be at high risk for migrating, which can cause life threatening side effects.

The study design was a non-randomized open label study without a control group, and such studies in MS can be hypothesis generating but are fraught with potential problems, as he clearly acknowledges in his conclusions (stating the design creates "a great potential for bias"). Nevertheless, it was a start in examining the theory. In terms of the results of the study, there was no statistically significant difference in the annualized relapse rate but relapsing-remitting MS patients were more likely to be relapse free than in the year prior to the study (27% versus 50 % relapse free). There was a reported reduction in gadolinium enhancement on MRI in those with relapsing remitting MS. People with RRMS also reported an improvement in quality of life. There were a number of challenges in interpreting the results. Most importantly, there was no control group. This is critical in MS studies, as in most clinical trials, even the group of people who do not get the treatment (placebo group) do better than they did the year prior to study entry, and if a treatment works, it must be found to produce a benefit significantly better than that seen in the placebo group. How relapses were defined in the year prior to and after the treatment was not explained, although this can significantly affect the reported relapse rates. The MRI scans were not done on any particular schedule and on different scanners, so the MRI portion is also tricky to interpret. Most of the relapsing remitting patients were also being treated with the current disease modifying therapies (a point somehow left out of the recent media reports of the treatment), so it is also difficult to separate out what factors might have been responsible for any improvement in disease activity. The measure used to measure disability was also one that is known to have a significant practice effect, which was not accounted for in the way it was administered in this study, so it was not possible to know if any early improvement was due to the practice effect or to a true treatment effect. Unfortunately the results were not very encouraging in those with progressive forms of MS, with only a weak inconsistent effect on quality of life but with no real benefit seen on other measures.

In the published report of his study, the conclusion reached by Dr. Zamboni was that his results warranted further study with a randomized double blind study of the treatment as an add-on therapy to current disease modifying therapies in relapsing-remitting MS. That means it would be tested in people with relapsing-remitting MS on one of the current disease modifying therapies and that half would get venoplasty and the other half would not. The two groups would then be compared with neither the examining neurologist nor the person themselves knowing whether or not they actually had the veins opened. It could then be determined whether there was a benefit to the procedure above the placebo effect. Subjects would also be followed closely to determine any risks associated with the procedure.

Although there were no serious side effects in Dr. Zamboni’s study, there was quite a high rate of recurrence of the vein narrowing. On the other hand, we now know from the experience at Stanford, that there can be significant risks to using stents to keep veins open. With their technique, there was one death and one case in which the stent migrated into the heart requiring emergency surgery, so clearly a safer approach is needed. In fact, their research was halted because of these serious adverse events. The treatment studies that are planned will help to define the risks of whatever approach is being tested. For now, it is generally agreed that venoplasty only be done as part of a controlled clinical trial, as would be the case for any new proposed treatment.

Although most researchers are focused on trying to whether the reported imaging abnormalities truly result in altered blood flow patterns and to determine the nature of the relationship between these venous findings and MS, there are others moving ahead already with clinical trials to test in a randomized study whether or not there really is a benefit to opening up the veins and how best to keep them open. Researchers in Buffalo have announced the initiation of a treatment trial and other groups have also indicated their intention to consider such studies. These planned treatment studies will attempt to define what the true benefits are from this treatment and will also better define the risks of different approaches. It will probably be tested first in those with relapsing-remitting MS as suggested by Dr. Zamboni. If it does indeed have a benefit in relapsing-remitting MS, then I would expect it would also be tested in progressive forms of the disease as his study was too small to draw a firm conclusion of lack of benefit in progressive MS.

In order for a treatment to be made available in Canada through public health care, there must be evidence from properly done clinical studies that:

1) the treatment provides a significant benefit over and above the placebo effect (comparing people actually having the procedure to those who just think they had it) and

2) that the potential benefits outweigh the potential risks.

Clinicians and researchers who work in the field of MS are keen to leave no stone unturned in the quest to end MS. Given the interest in this subject, which helps make research funds available to study it, research is likely to move ahead quite quickly in this area. Keep posted on the MS Society website for reports on developments in this and other areas of research as they become available.

DISCLAIMER: Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.

Bookmark and Share

Sunday, March 14, 2010

reBlog from The Wheelchair Kamikaze: Wheelchair Kamikaze

Okay, folks, here's the skinny on my experience undergoing the CCSVI "Liberation Procedure", and the results obtained from it. For those unaware of what CCSVI or the Liberation Procedure are, please click here.
The Wheelchair Kamikaze, Wheelchair Kamikaze, Mar 2010
You should read the whole article.

Saturday, March 13, 2010

MS – CCSVI Liberation Treatment Update
Bookmark and Share
Reblog this post [with Zemanta]

Thursday, March 11, 2010

The Multiple Sclerosis Society of Canada will be holding a webcast for the general public and the media on the topic of chronic cerebrospinal venous insufficiency (CCSVI) and MS.
Read more

Bookmark and Share

Wednesday, March 10, 2010

This definetly is one of my heros. Love Rick Hansen
Bookmark and Share

Sunday, March 7, 2010

reBlog from The Wheelchair Kamikaze: Wheelchair Kamikaze

This Wednesday, March 10, I'm scheduled to undergo a diagnostic venogram, looking for stenosis (narrowing) and/or other abnormalities in my azygos and jugular veins. If any such anomalies are found, they will be addressed via a balloon procedure. The venogram itself involves feeding a catheter from a vein in my upper thigh, through my vascular system, to the veins associated with the central nervous system. In the parlance of CCSVI, this is known as the "Liberation Procedure". (For info on CCSVI, click here)The Wheelchair Kamikaze, Wheelchair Kamikaze, Mar 2010

You should read the whole article.

Tuesday, March 2, 2010

Monday, March 1, 2010

World MS Day 26 May 2010
view video
Bookmark and Share